|Bid||3,600.00 x 51000|
|Ask||4,094.50 x 53800|
|Day's range||3,603.50 - 3,785.50|
|52-week range||3,603.50 - 5,377.00|
|PE ratio (TTM)||111.17|
|Earnings date||27 Oct 2017|
|Dividend & yield||0.26 (0.55%)|
|1y target est||69.61|
Update: I spoke with Shire (SHPG) CFO Jeff Poulton about his decision to leave, and he was quick to dispel any concerns that his departure was about anything except his desire to pursue a new opportunity. Poulton also said that calling Shire a specialty-pharmaceutical company is a misnomer, as an overwhelming percentage of revenue now comes from its orphan drug business, a point raised by analyst Evercore ISI analyst Josh Schimmer, who wrote that Shire has "biotech cash flows with a spec pharma valuation" in a note last week. Shares of Shire have fallen 4% to $139.71 at 1:26 p.m. today.
Charlestown-based agricultural technology startup Indigo Inc. announced Monday that it is bringing on Jeff Poulton, the chief financial officer of pharmaceutical giant Shire plc, as its own CFO. Poulton will leave Shire at the end of the year, according to the Irish drugmaker. "It has been a privilege to work for Shire and to have played a part in the exceptional growth story of such an inspirational company," Poulton said in a statement.
Pharmaceutical company Shire (Hamburg: 3979575.HM - news) said its chief financial officer Jeff Poulton will stand down at the end of the year to join Indigo Ag, a Boston-based start-up that seeks to improve agricultural productivity. Poulton, who joined Shire (Xetra: S7E.DE - news) in 2003, has been CFO since January 2015, a period that saw Shire make its largest acquisition with the $32 billion purchase of Baxalta (Xetra: 9BX.DE - news) last year.